Capital Insight Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Capital Insight Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,443	Closed	-$203K	–	171
2023 Q2	$203K	Sell	2,443 -852	-26%	-$71.3K	0.05%	170
2023 Q1	$251K	Sell	3,295 -855	-21%	-$70.9K	0.06%	151
2022 Q4	$344K	Sell	4,150 -2,065	-33%	-$167K	0.09%	127
2022 Q3	$493K	Sell	6,215 -8,513	-58%	-$718K	0.13%	110
2022 Q2	$1.09M	Sell	14,728 -1,620	-10%	-$122K	0.26%	99
2022 Q1	$1.47M	Sell	16,348 -785	-5%	-$72.5K	0.3%	100
2021 Q4	$1.92M	Sell	17,133 -3,052	-15%	-$368K	0.39%	92
2021 Q3	$2.54M	Sell	20,185 -172	-0.8%	-$22.1K	0.55%	66
2021 Q2	$2.76M	Sell	20,357 -383	-2%	-$50.4K	0.62%	62
2021 Q1	$2.81M	Sell	20,740 -767	-4%	-$115K	0.68%	54
2020 Q4	$3.03M	Sell	21,507 -1,140	-5%	-$146K	0.76%	43
2020 Q3	$2.52M	Buy	22,647 +4,031	+22%	+$452K	0.71%	51
2020 Q2	$2.08M	Buy	+18,616	New	+$1.83M	0.66%	53

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Capital Insight Partners's XBI Position: Q3 2023 in Review

Capital Insight Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2023, closing a stake of 2,443 shares — an estimated $203K sold.

Capital Insight Partners first reported a position in XBI in Q2 2020 and held it in 13 quarters. The position peaked at $3.03M in Q4 2020. 677 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

Capital Insight Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2023 after selling out during the quarter.
Capital Insight Partners sold 2,443 State Street SPDR S&P Biotech ETF shares in Q3 2023, an estimated $203K.
Capital Insight Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 13 quarters.
Capital Insight Partners's State Street SPDR S&P Biotech ETF position peaked at $3.03M in Q4 2020.
677 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on Capital Insight Partners's 13F filing for Q3 2023, filed 30 Oct 2023.